Epidemiologic and Etiologic Considerations in Malignant Melanoma

  • Larry Nathanson
Part of the Cancer Treatment and Research book series (CTAR, volume 9)

Abstract

Hippocrates first described melanoma in the fifth century B.C., and the disease has been identified in mummies of the pre-Columbian Incas of Peru [1]. The disease was first identified in the modern literature by Laennec, in 1806, and by Norris in the English literature in 1820 [2]. The English name melanoma was given to the disease by Carswell in 1838. The pathology of the disease, and its natural history, was first described by Handley in 1907 [3] and appropriate surgical management by Spencer in 1923 [4]. The literature describing every ramification of this disease has been profuse in modern times, and appears to far outmeasure its incidence rate.

Keywords

Foam Arsenic Oncol Psoriasis Prolactin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Urteaga OB, Pack GT: On the antiquity of melanoma. Cancer 19: 607–610, 1966.PubMedGoogle Scholar
  2. 2.
    Norris W: A case of fungoid disease. Edinb Med Surg J 16: 562–565, 1820.Google Scholar
  3. 3.
    Handley WS: The pathology of melanotic growths in relation to their operative treatment. Lancet 1: 927–933, 1907.Google Scholar
  4. 4.
    Spencer WG: Melanosis, melanin, melanoma and melanotic cancer. Brit Med J 2: 907, 1923.PubMedGoogle Scholar
  5. 5.
    Nathanson L: Malignant melanoma. In: Guide to therapeutic oncology, Bergevin PR, Blom J, Tormey DC (eds). Williams & Wilkens, 1979, pp 538–561.Google Scholar
  6. 6.
    Nathanson L: Spontaneous regression of malignant melanoma: A review of the literature of incidence, clinical features, and possible mechanisms. Nat Cancer Inst Monogr 44: 67–76, 1976.PubMedGoogle Scholar
  7. 7.
    Kripke ML: Speculations on the role of ultraviolet radiation in the development of malignant melanoma. JNCI 63: 541–545, 1979.PubMedGoogle Scholar
  8. 8.
    Editorial. Lancet: 172–174, 1971.Google Scholar
  9. 9.
    Editorial. Lancet: 253–254, 1981.Google Scholar
  10. 10.
    Ariel IM: Theories regarding the cause of malignant melanoma. Surg Gyn & Obs 150: 907–917, 1980.Google Scholar
  11. 11.
    Balch CM, Soong S, Milton GW, Shaw HM, McGovern VJ, Murad TM, Maddox WA: Changing trends in cutaneous melanoma over a quarter century in Alabama, USA and New South Wales, Australia. Cancer. In Press 1983.Google Scholar
  12. 12.
    Bagley FH, Cady B, Lee A, Legg MA: Changes in clinical presentation and management of malignant melanoma. Cancer 47: 2126–2134, 1981.PubMedGoogle Scholar
  13. 13.
    Griffel M: survival of cutaneous malignant melanoma patients at University of Iowa hospitals; 1950–1974. Cancer 47:176–183, 1981.PubMedGoogle Scholar
  14. 14.
    McGovern VJ: Epidemiological aspects of melanoma: A review. Pathology 9: 233–241, 1977.PubMedGoogle Scholar
  15. 15.
    Klepp O, Magnus K: Some environmental and bodily characteristics of melanoma patients: A case control study. Int J Cancer 23: 482–486, 1979.PubMedGoogle Scholar
  16. 16.
    Schreiber MM, Bozzo PD, Moon TE: Malignant melanoma in Southern Arizona: Increasing incidence and sunlight as an etiologic factor. Arch Dermatol 117: 6–11, 1981.PubMedGoogle Scholar
  17. 17.
    McCarthy, WH, Black Al, Milton GW: Melanoma in New South Wales: An epidemiologic survey 1970–1976. Cancer 46: 427–432, 1980.PubMedGoogle Scholar
  18. 18.
    Elwood JM, Lee JAH: Recent data on the epidemiology of malignant melanoma. Semin Oncol 2, 1975.Google Scholar
  19. 19.
    Hakulinen T, et al: Cancer of the eye: a review of trends and differentials. WHO Stat Quart 31: 143–158, 1978.Google Scholar
  20. 20.
    Swerdlow Al: Sunlight exposure and melanoma. Brit Med J 2: 1324–1327, 1979.Google Scholar
  21. 21.
    Daniels F Jr: Sunlight. In: Cancer epidemiology and prevention: Current concepts, Schottenfeld D (ed). CC Thomas, 1975, pp 126–152.Google Scholar
  22. 22.
    Houghton A, Flannery J, Viola MV: Malignant melanoma in Connecticut and Denmark. Int. J Cancer 25: 95–104, 1980.PubMedGoogle Scholar
  23. 23.
    Elwood JM, Lee JAH: Recent data on the epidemiology of malignant melanoma. In: Human malignant melanoma, Clark WH, Goldman LI, Mastrangelo MI (eds). Grune & Stratton, 1979.Google Scholar
  24. 24.
    Sober AJ, Lew RA, Fitapatrick TB, Marvell R: Solar exposure patterns in patients with cutaneous melanoma: A case control series. Clin Res 27: 536, 1979.Google Scholar
  25. 25.
    Baker-Blocker A: UV radiation and melanoma mortality in the United States. Environ Res 23: 24–28, 1980.PubMedGoogle Scholar
  26. 26.
    Teppo L, Pakkanen M, Hakulinen T: Sunlight as a risk factor of malignant melanoma of the skin. Cancer 41: 2018–1027, 1978.PubMedGoogle Scholar
  27. 27.
    Rose EF: Pigment variation in relation to protection and susceptibility to cancer. Pigment Cell 1: 236–245, 1973.Google Scholar
  28. 28.
    Coleman WP, Loria PR, Reed RJ: Acral lentiginous melanoma. Arch Dermatol 116: 773–776, 1980.PubMedGoogle Scholar
  29. 29.
    Mori W: Geographicapathology of malignant melanoma in Japan. Pigment Cell 1: 246–254, 1973.Google Scholar
  30. 30.
    Smith AC, Egan EA: The role of epidemiological investigations in the study of ocular tumors. Int Ophth Clin 20: 63–69, 1980.Google Scholar
  31. 31.
    Morton WE: Epidemiologic clues to the cause of melanoma. Western J Med 131: 263–269, 1979.Google Scholar
  32. 32.
    Maugh TH: Ozone depletion would have dire effects. Science 207: 394–395, 1980.PubMedGoogle Scholar
  33. 33.
    Stratospheric ozone depletion by halocarbons - chemistry and transport. Panel on stratospheric chemistry and transport, Natl Academy of Science, 1979.Google Scholar
  34. 34.
    Protection against depletion of stratospheric ozone by chlorofluorocarbons. Committee on impacts of stratospheric change. Assembly of mathematical and phycical science, Natl Acad Sci, 1979.Google Scholar
  35. 35.
    Norman C: Satellite data indicate ozone depletion. Science 213: 1088–9, 1981.PubMedGoogle Scholar
  36. 36.
    Viola MV, Houghton A, Munster EW: Solar cycles and malignant melanoma. Med Hypoth 5: 153–160, 1979.Google Scholar
  37. 37.
    Willimas RR, Stegens NL, Goldsmith JR: Associations of cancer site and type with occupation and industry from the third natl cancer survey interview. J Natl Cancer Inst 59: 1147, 1977.Google Scholar
  38. 38.
    Thomas TL, Decoufle P: Mortality among workers employed in the pharmaceutical industry: a preliminary investigation. J Occup Med 21: 619–623, 1979.PubMedGoogle Scholar
  39. 39.
    Blot WJ, Brinton LA, Fraumeni JF, et al: Cancer mortality in US countries with petroleum industries. Science 198: 51–53, 1977.PubMedGoogle Scholar
  40. 40.
    Albert DM, et al: Increased incidence of chloroidal malignant melanoma occurring in a single population of chemical workers. Am J Ophth 89: 323–3337, 1980.PubMedGoogle Scholar
  41. 41.
    Anchev N, Popov IV, Ikonopisov RL: Epidemiology of malignant melanoma in Bulgaria. In: Structure and control of the melanocyte, Muhlbach O, Porta G (eds). Springer-Verlag, 1966, pp 286–291.Google Scholar
  42. 42.
    Lee J A, Strickland D: Malignant melanoma: Social status and outdoor work. Br J Cancer 41: 757–763, 1980.PubMedGoogle Scholar
  43. 43.
    Dickson D: Melanoma increase in radiation labs? Nature 1: 287, 1980.Google Scholar
  44. 44.
    Bahn AK, Rosenwaike I, Hermann N, et al: Melanoma after exposure to PCB’s. N Engl J. Med 295: 450, 1976.PubMedGoogle Scholar
  45. 45.
    Dyer R: Tear gas and skin cancer. Washington Post, March 1975.Google Scholar
  46. 46.
    Clough P: Incidence of malignant melanoma of the skin in England and Wales. Brit Med J 280: 112, 1980.PubMedGoogle Scholar
  47. 47.
    Bartal AH, Cohen Y, Robinson E: Malignant melanoma arising at tattoo sites used for radiotherapy field marking. Brit J Rad 53: 913–914, 1980.Google Scholar
  48. 48.
    Beral V, Ramcharan S, Faris R: Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 36: 804–809, 1977.PubMedGoogle Scholar
  49. 49.
    Lerner AB, Nordlund JJ, Kirkwood JM: Effects of oral contraceptives and pregnancy on melanomas. NEJM 47: 301, 1979.Google Scholar
  50. 50.
    Stevens RG: Oral contraceptives and malignant melanoma. NEJM: 302: 966, 1980.PubMedGoogle Scholar
  51. 51.
    Chaudhuri PK, Walker MJ, DasGupta TK: Cutaneous malignant melanoma after immunosuppressive therapy. Arch Surg 115: 322–323, 1980.PubMedGoogle Scholar
  52. 52.
    Fletcher WS, Palmer S: Malignant melanoma: The red flag of oncogenesis. Pigment Cell 2: 427–432, 1976.Google Scholar
  53. 53.
    Hardie IR, Strong RW, Hartley LC, et al: Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 87: 177, 1980.PubMedGoogle Scholar
  54. 54.
    Hoover R, Fraumeni JF, Jr: Drug-induced cancer. Cancer 47: 1071–1080, 1981.PubMedGoogle Scholar
  55. 55.
    Skibba JL, Pinckley J, Gilbert EF, Johnson RO: Multiple primary melanoma following administration of L-Dopa. Archs Path 9: 556–561, 1972.Google Scholar
  56. 56.
    Robinson E, Wajaskort J, Hirshowitz B: L-Dopa and Malignant melanoma. Arch Path 95: 213, 1973.PubMedGoogle Scholar
  57. 57.
    Sober AJ, Fitzpatrick TB: Genetic and environmental factors of malignant melanoma in man. Pigment Cell 5: 88–94, 1979.Google Scholar
  58. 58.
    Stern RS, Zierler S, Parrish JA: Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1: 732–735, 1980.PubMedGoogle Scholar
  59. 59.
    Cole RS: Repair of interstrand crosslinks in DNA induced by psoralen plus light. Yale J Bio and Med 46: 492, 1973.Google Scholar
  60. 60.
    Lane-Brown MM, et al: Sunscreen misconception. Med J Aust 6: 282, 283, 1980.Google Scholar
  61. 61.
    Holman CDJ, Armstrong BK, James IR: Sunscreen misconception. Med J Aust 1: 669, 1980.PubMedGoogle Scholar
  62. 62.
    Mackie BS, Johnson AR, Macki LE, Fogerty AC, Ferris M, Baxter RI: Dietary polyunsaturated fats and malignant melanoma. Med J Aust 1: 159–163, 1980.PubMedGoogle Scholar
  63. 63.
    Donovan JW: Comment on dietary polyunsaturated fats and malignant melanoma: One way to improve the quality of clinical research in Australia. Med J Aust 1: 163, 1980.PubMedGoogle Scholar
  64. 64.
    Williams RR: Breast and thyroid cancer and malignant melanoma promoted by alcohol- induced pituitary secretion of prolactin, TSH, and MSH. Lancet 1: 996–999, 1976.PubMedGoogle Scholar
  65. 65.
    Shaw HM, Milton GW, McCarthy WH, Farago GA, Dilworth P: Effect of smoking on the recurrence of malignant melanoma. Med J Aust 1: 208–209, 1979.PubMedGoogle Scholar
  66. 66.
    Russ, JE, Scanlon EF: Identical cancers in husband and wife. SGO 150: 664–667, 1980.PubMedGoogle Scholar
  67. 67.
    Robertson R: Connubial melanoma. JAMA 217: 1553, 1971.PubMedGoogle Scholar
  68. 68.
    Kopf AW, Mintzis M, Grier RN, Silvers DN, Bart RS: Familial malignant melanoma. Cutis 17: 873–876, 1976.PubMedGoogle Scholar
  69. 69.
    Albert DM: The association of viruses with uveal melanoma. Trans Am Ophth Soc 77: 367–421, 1979.Google Scholar
  70. 70.
    Coleman WP, III, Loria PR, Reed RJ: Acral lentiginous melanoma. Arch Dermatol 116: 773–777, 1980.PubMedGoogle Scholar
  71. 71.
    Ghadially FN: Trauma and melanoma production. Nature 211: 1199, 1966.PubMedGoogle Scholar
  72. 72.
    Anaise D, Steinitz R, Hur NB: Solar radiation: A possible etiological factor in malignant melanoma in Israel. Cancer 42: 299–304, 1978.PubMedGoogle Scholar
  73. 73.
    Kolonel LN: Cancer patterns of four ethnic groups in Hawaii. JNCI 65: 1127, 1980.PubMedGoogle Scholar
  74. 74.
    Clark DA, Necheles TF, Nathanson L, Whiteen D, et al: Apparent HLA-5 deficiency in human malignant melanoma. Israel J Med Sci 10: 836–840, 1974.Google Scholar
  75. 75.
    Pellegris G, Illeni MT, Vaglinim KD, Cascinell N, Masserini C: HLA antigens in malignant melanoma patients. Tumori 66: 151–158, 1966.Google Scholar
  76. 76.
    Terasaki PI, Perdue ST, Mickey MR: HLA frequencies in cancer: A second study. In: Genetics of human cancer, Mulvihill JJ, Miller RW, Fraumeni JF (eds). Raven Press, 1977.Google Scholar
  77. 77.
    Nathanson SD, Park MS, Drew SI, Morton DL, Terasaki PI: First and second B-lymphocyte antigen expression in malignant melanoma. Trans Pro 12: 118–20, 1980.Google Scholar
  78. 78.
    Clark WH, et al: Origin of familial malignant melanomas from heritable melanocytic lesions: Origin of familial malignant melanomas from heritable melanocytic lesions, ‘the B-K mole syndrome’. Arch Dermatol 114: 732–738, 1978.PubMedGoogle Scholar
  79. 79.
    Lynch HT, Frichot BC, Lynch JF: Familial atypical multiple mole-melanoma syndrome. J Med Genet 15: 352–356, 1978.PubMedGoogle Scholar
  80. 80.
    Reimer RR, Clark WH, Greene MH, Ainsworth AM, Fraumeni JF: Precursor lesions in familial melanoma: A new genetic preneoplastic syndrome. JAMA 239: 744–746, 1978.PubMedGoogle Scholar
  81. 81.
    Cawley EP, Kruse WT, Pinkus HK: Genetic aspects of malignant melanoma. AMA Arch Derm Syph 65: 440–450, 1952.Google Scholar
  82. 82.
    Lynch HT, Lynch J, Lynch P: Management and control of familial cancer. In: Genetics of human cancer, Mulvihill JJ, Miller RW, Fraumeni JF Jr. Raven Press, 1977, pp 245–256.Google Scholar
  83. 83.
    Greene MH, Fraumeni JF: The heredity variant of malignant melanoma. In: Human malignant melanoma, Clark WH, Goldman LI, Mastrangelo MJ (eds). Grune & Stratton, 1979.Google Scholar
  84. 84.
    Anderson DE, Smith JL, McBride M: Heredity aspects of malignant melanoma. J Amer Med Ass 200: 741, 1967.Google Scholar
  85. 85.
    Bellet RE, Shields JA, Soli DB, Bernardino EA: Primary choroidal and cutaneous melanomas occuring in a patient with the B-K mole syndrome phenotype. Am J Ophth 89: 567–570, 1980.PubMedGoogle Scholar
  86. 86.
    Kakati S, Song SY, Sandberg AA: Chromosomes and causation of human cancer and leukemia. Cancer 40: 1173–1181, 1977.PubMedGoogle Scholar
  87. 87.
    Lutzner MA: Nosology among the neoplastic genodermatoses. In: Genetics of human cancer, Mulvihill JJ, Miller RW, Fraumeni JF (eds). Raven Press, 1977.Google Scholar
  88. 88.
    Mulvihill JJ: Genetic repertory of human neoplasia. In: Genetic of human cancer, Mulvihill JJ, Miller RW, Fraumeni JF (eds). Raven Press, 1977.Google Scholar
  89. 89.
    Greene MH, Mead GD, Reimer RR, Bergfeld WF, Fraumeni JF: Malignant melanoma and Charcot-Marie-Tooth disease. AJMG 5: 69–71, 1980.Google Scholar
  90. 90.
    Reed WB, Becker SW, Becker SW Jr, et al: Giant pigmented nevi, melanoma and leptomeningeal melanocytosis. Arch Dermatol 91: 100–119, 1965.PubMedGoogle Scholar
  91. 91.
    Lynch HT, Anderson DE, Smith JL Jr, et al: Xeroderma pigmentosum, malignant melanoma and congenital ichtyosis. Arch Dermatol 96: 625–636, 1967.PubMedGoogle Scholar
  92. 92.
    Moore C, Iverson PC: Xeroderma showing common skin cancer plus melanocarcinoma controlled by surgery. Cancer 7: 377–382, 1954.PubMedGoogle Scholar
  93. 93.
    Iijima S, Watanabe S, Shimoda C: A case of xeroderma pigmentosum with melanoma: A report of a case with a review of the literature. Acta Dermatol 52: 163–167, 1957.Google Scholar
  94. 94.
    Lynch HT, Lynch PM, Albano WA, Edney J, Organ CH, Lynch JF: Heredity cancer: Ascertainment and management. CA 4: 216–232, 1979.Google Scholar
  95. 95.
    Sagebiel RW: Age and site distributions in the early and borderline malignant melanoma of human skin. Clin Res 27: 138A, 1979.Google Scholar
  96. 96.
    Gilchrest BA, Blog FB, Szabo G: Effects of aging and chronic sun exposure on melanocytes in human skin. J Invest Dermatol 73: 141–143, 1979.PubMedGoogle Scholar
  97. 97.
    Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH: Dysplastic nevus syndrome: A phenotypuc association of sporadic cutaneous melanoma. Cancer 46: 1787–1794, 1980.PubMedGoogle Scholar
  98. 98.
    Tucker SB, Horstmann JP, Hertel B, Aranha G, Rosa J: Activation of nevi in patients with malignant melanoma. Cancer 46: 822–827, 1980.PubMedGoogle Scholar
  99. 99.
    Nathanson L, Vanter G, Hall TC: Unpublished observation, 1969. (see p 16).Google Scholar
  100. 100.
    Shaw HM, McGovern VJ, Milton GW, Farago GA, McCarthy WH: Malignant melanoma: Influence of site of lesion and age of patient in the female superiority in survival. Cancer 46: 2731–2735, 1980.PubMedGoogle Scholar
  101. 101.
    Houghton AN, Falnnery J, Viola MV: Malignant melanoma of the skin occurring during pregnancy. Cancer 48: 407–410, 1981.PubMedGoogle Scholar
  102. 102.
    McCarty KS, Wortman J, Stowers S, Lubahn DB, McCarty KS, Seigler HF: Sex steroid receptor analysis in human melanoma. Cancer 46: 1463–1470, 1980.PubMedGoogle Scholar
  103. 103.
    Hersey P, Morgan G, Stone DE, et al: Previous pregnancy as a protective factor against death from melanoma. Lancet 1: 451–454, 1977.PubMedGoogle Scholar
  104. 104.
    Weiss NS, Falnnery JT: The relationship of marital status to survival from melanoma. Cancer 42: 296–298, 1978.PubMedGoogle Scholar
  105. 105.
    Lee JA, Storer BE: Excess of malignant melanomas in women in the British Isles. Lancet 2: 1337–1339, 1980.PubMedGoogle Scholar
  106. 106.
    Sadoff L, Windley J, Tyson S: Is malignant melanoma an endocrine-dependent tumor? Oncology 27: 244–257, 1973.PubMedGoogle Scholar
  107. 107.
    Bhakoo HS, Milholland RJ, Lopez R, Karakousis C, Rosen F: High incidence and characterization of glucocorticoid receptors in human malignant melanoma. JNCI 66: 21–25, 1981.PubMedGoogle Scholar
  108. 108.
    Creagan ET, Ingle JN, Woods JE, Pritchard DJ, Jiang NS: Estrogen receptor in patients with malignant melanoma. Cancer 46: 1785–1786, 1980.PubMedGoogle Scholar
  109. 109.
    Chaudhuri PK, Walker MJ, Briele HA, et al: Incidence of estrogen receptor in benign nevi and human malignant melanoma. JAMA 244: 791–793, 1980.PubMedGoogle Scholar
  110. 110.
    Epstein JH, Epstein WL, Kakai T: Production of melanomas from DMBA-induced ‘blue nevi’ in hairless mice with ultraviolet light. J Natl Cancer Inst 38: 19–30, 1967.PubMedGoogle Scholar
  111. 111.
    Kripke ML: Latency, histology and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 37: 1395–1400, 1977.PubMedGoogle Scholar
  112. 112.
    Kripke MK: Speculation on the role of ultraviolet radiation in the development of malignant melanoma. JNCI 63: 541–545, 1979.PubMedGoogle Scholar
  113. 113.
    Vesselinovitch SO, Mihailovich N, Richter WR: The induction of malignant melanomas in Syrian white hamster by neonatal exposure to urethan. Cancer Res 30: 2543–2547, 1970.PubMedGoogle Scholar
  114. 114.
    Oberman B, Riviere MR: Experimental melanoma in hamsters. In: Structure and control of the melanocyte, sixth international pigment cell conference sponsored by the International Union Against Cancer, Porta GD, Muhlbock O (eds). Springer-Verlag, 1966.Google Scholar
  115. 115.
    Chernozemski I: Changes in the skin of the Syrian hamster after a single application of 9,10-Dimenthyl-1,2-benzanthracene. In: Structure and control of the melanocyte, sixth international pigment cell conference sponsored by the International Union Against Cancer, Porta GD, Muhlbock O (eds). Springer-Verlag, 1966.Google Scholar
  116. 116.
    Pawlowski A, Haberman HF, Menon IA: Skin melanoma induced by 7,12-dimethylben- zanthracene in albino guinea pigs and its similarities to skin melanoma of humans. Cancer Res 40: 3652–3660, 1980.PubMedGoogle Scholar
  117. 117.
    Benson WR: Intraocular tumor after ethionine and N-2 fluorenylacetamide. Arch Pathol 73: 404, 1962.PubMedGoogle Scholar
  118. 118.
    Rose JR, Harschbarger JE: Melanoma in the salamander. Science, April 2, 1979.Google Scholar
  119. 119.
    Siciliano MJ, Morizot DC, Wright DA: Factors responsible for platyfish-swordtail hybrid melanoma - Many or few? Pigment Cell 2: 47–58, 1976.Google Scholar
  120. 120.
    Millikan LE, Hook RR, Manning PJ: Gross and ultrastructural studies in a new melanoma model: The Sinclair swine. Yale J Bio and Med 46: 631–645, 1973.Google Scholar
  121. 121.
    Levene A: Comparative aspects of the melanoma of grey and white horses: A unique proliferative disorder of pigment production. In: Structure and control of the melanocyte, sixth international pigment cell conference sponsored by the International Union Against Cancer, Porta GD, Muhlbock O (eds). Springer-Verlag, 1966.Google Scholar
  122. 122.
    Taylor GN, Dougherty TF, Mays CW, Atherton DR, Jee WSS: Radium-induced eye melanoma in dogs. Radiat Res 5: 361, 1972.Google Scholar
  123. 123.
    Sayre RM, Marlowe E, Agin P, LeVee GL, Rosenberg W: Performance of six sunscreen formulations on human skin. Arch Dermatol 115: 46–49, 1979.PubMedGoogle Scholar
  124. 124.
    Epstein JH: Suntan salons and the American skin. So Med J 74: 837–840, 1981.Google Scholar
  125. 125.
    Editorial: Sunscreens, photocarcinogenesis, melanogenesis, and sporalens. Brit Med J 283: 335–336, 1981.Google Scholar
  126. 126.
    Nachtwey DS, Rundel RD: A photobiological evaluation of tanning booths. Science 211: 405–407, 1981.PubMedGoogle Scholar
  127. 127.
    Pearse AD, Wolska H, Marks R: Do sunscreens prevent premalignant change in the epidermis? (meeting abstract). Br J Dermatol 101: 22, 1979.Google Scholar
  128. 128.
    Levine N, Meyskens FL: Topical vitamin-A-acid therapy for cutaneous metastatic melanoma. The Lancet 2: 224–226, 1980.Google Scholar
  129. 129.
    Balda BR, Hehlmann R, Cho JR, et al: Oncornavirus-like particles in human skin cancers. Proc Natl Acad Sci USA 72: 3697–3700, 1975.PubMedGoogle Scholar
  130. 130.
    Parsons PG, Klucis E, Goss PD, Pope JH, Little JH, Davis NC: Oncornavirus-like particles in malignant melanoma and control biopsies. Intl J Cancer 18: 757–763, 1976.Google Scholar
  131. 131.
    van Teighem N, Vercammen-Grandjean A, Beaumont L, et al: Pseudotypes of the oncornavirus VSV after culture in a human melanoma. Arch Int Physiol Bio 86: 213–214, 1978.Google Scholar
  132. 132.
    Scola-Nagelschneider G, Balda BR: Species specificity of RNA-directed DNA polymerase in melanomas. J Clin Hematol Oncol 261: 100, 1978.Google Scholar
  133. 133.
    Brown SG, Parsons PG, Pope JH: Search for human tumour virtises by transfection: Uptake of melanoma and Epstein-Barr virus DNA by human cells. Aust J Exp Biolo Med Sci 57: 1–7, 1979.Google Scholar
  134. 134.
    Gregerson DS, Reid TW: Hamster melanoma virus: A unique retrovirus. Pigmant Cell 5: 129–135, 1979.Google Scholar
  135. 135.
    Takahashi M, Mishima Y: A sequence of virus-like particle formation in the ergastoplasm of Greene’s malignant melanoma cells. Cancer 24: 904–911, 1969.PubMedGoogle Scholar
  136. 136.
    Ito R, Mishima Y: Particles in the cisternae of the endoplasmic reticulum of Fortner’s amelanotic and melanotic malignant melanomas. J Invest Dermatol 48: 268–272, 1967.PubMedGoogle Scholar
  137. 137.
    Albert DM, Lahav M, Colby ED, et al: Retinal neoplasia and dysplasia: induction by feline leukemia virus. Invest Ophth Visual Sci 16: 325–337, 1977.Google Scholar
  138. 138.
    Russell P, Gregerson DS, Albert DM, Reid TW: Characteristics of a retrovirus associated with a hamster melanoma. J Gen Virol 43: 317–326, 1979.PubMedGoogle Scholar
  139. 139.
    Beral V, Shaw H, Evans S, Milton G: Malignant melanoma and exposure to fluorescent lighting at work. The Lancet 2: 290–293, 1982.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague/Boston/London 1983

Authors and Affiliations

  • Larry Nathanson

There are no affiliations available

Personalised recommendations